Loading organizations...
Longaeva operates as an investment management firm specializing in global equity markets. The company focuses on delivering industry-leading returns through diverse ideas and strategic decision-making, while also targeting investments in technologies related to human lifespan extension and health improvement. Its approach emphasizes creating enduring value by harnessing market opportunities.
Longaeva Partners LP was established in 2024, based in New York. The firm draws its name from the longaeva pine, a symbol of longevity, adaptability, and persistence, which underpins its investment philosophy. The founding insight centered on applying a resilient and forward-looking strategy to investment management. Specific founders are not publicly detailed.
The firm serves investors seeking long-term value and capital growth in global equities, particularly those interested in advancements in human health and longevity. Longaeva's vision centers on shaping the future of investing by transforming market challenges into opportunities and generating lasting impact and smarter decisions for its partners and the broader investment landscape.
Longaeva has 2 tracked investments across 2 companies. The latest tracked deal is $100.0M Other Equity in Imperative Care in March 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 17, 2026 | Imperative Care | $100.0M Other Equity | Elevage Medical Technologies, Perceptive Advisors | Ally Bridge Group, Bain Capital Life Sciences, Brown Advisory, Catalio Capital |
| Sep 1, 2025 | Galvanize Therapeutics | $100.0M Series C | Soffinova Partners | Jonathan Waldstreicher, Seth L. Harrison, ATP (apple Tree Partners), Norwest Venture Partners, Ally Bridge Group, Apple Tree Partners, Elevage Medical Technologies, Fidelity Management & Research Company, David Lewis, Intuitive Ventures, Janus Henderson Investors, Zack Scott, Perceptive Xontogeny Venture Fund, T. Rowe Price Associates |
